Opinion|Videos|July 29, 2024
Dose Modifications & Patient Adherence Strategies for Managing Toxicities CDK 4/6 Inhibitors
A panel of experts discuss the variables of dosage and patient adherence in regards to managing toxicities from CDK4/6 inhibitors.
Advertisement
Video content above is prompted by the following question(s):
- What is the impact of dose modifications or interruptions on treatment outcomes with CDK4/6 inhibitors in the adjuvant setting?
- What has your experience been with toxicities and their management impacting patient adherence to CDK4/6 inhibitors in the adjuvant setting, and what strategies have you used to help improve this?
Advertisement
Related Content
Advertisement
Advertisement
Trending on AJMC
1
FDA OKs Zidesamtinib as New Option for Resistant ROS1+ NSCLC
2
Cognitive Rehabilitation Improves Functional Outcomes in Long COVID Brain Fog
3
PMOS Linked to 4-Fold Atherosclerotic Heart Disease Risk in 2.5 Million US Women
4
CAR T-Cell Therapy Shows Promise in Refractory Myasthenia Gravis, Evidence Still Limited
5